Healthcare / Drug Manufacturers - Specialty & GenericNSE
$270.10
-1.45 (-0.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-130.3M · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
46.3x
↑EV/EBITDA
16.9x
↑ROE
3.5%
↑Gross Margin
48.5%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+12.0%
FCF CAGR
—
FCF margin
-19.2%
FCF / Net income
-3.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.98B · net income $96.4M · FCF $-379.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.98B | $1.98B | $1.63B | $1.79B | $1.41B |
| Net Income | $96.4M | $96.4M | $71.1M | $109.3M | $148.4M |
| EBITDA | $227.0M | $227.0M | $201.0M | $245.7M | $263.3M |
| EPS | 7.22 | 7.22 | 5.16 | 8.63 | 11.73 |
| Gross Margin | 48.5% | 48.5% | 47.9% | 38.9% | 39.0% |
| Operating Margin | 6.3% | 6.3% | 4.2% | 9.7% | 13.4% |
| Net Margin | 4.9% | 4.9% | 4.4% | 6.1% | 10.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.16 | 0.15 | 0.13 |
| Current Ratio | 2.54 | 2.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-379.5M | $-379.5M | $-103.5M | $-130.3M | $-128.9M |
| Returns | |||||
| ROE | 3.5% | 3.5% | 3.4% | 5.3% | 7.7% |
| Valuation | |||||
| P/E | 46.25 | 46.25 | 96.98 | 51.83 | 58.87 |
| EV/EBITDA | 16.87 | 16.87 | 33.14 | 23.73 | 33.37 |
| P/B | 1.33 | 1.33 | 3.00 | 2.76 | 4.52 |
| Growth & Yield | |||||
| Revenue Growth | 21.7% | 21.7% | -9.3% | 27.3% | — |
| EPS Growth | 39.9% | 39.9% | -40.2% | -26.4% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
49.2%
EPS terminal req.
$23.97
Spread vs growth
-9.3%
5Y implied EPS CAGR
32.1%
EPS terminal req.
$29.00
Spread vs growth
7.9%
10Y implied EPS CAGR
20.5%
EPS terminal req.
$46.70
Spread vs growth
19.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.7%
Start / end P/E
83.2x → 37.4x
EPS bridge
5.16 → 7.22
Residual
-22.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.